ABOUT PRETERMX
Preterm birth is the leading cause of neonatal mortality and a lifelong burden for the families it touches. Yet clinicians today rely on therapies that were never designed for the uterus — systemic, off-label, and dose-limited by side effects.
PretermX is changing that by developing the first therapeutics engineered to act directly on the uterus, giving clinicians a safer and more durable way to stop preterm labor at its source.
Building a new category
of precision medicine
TEAM
Built by scientists who dedicated their careers to solving preterm birth
Our team combines years of research, translational science, and problem-solving focused on preterm birth.
We are united by our goal to turn rigorous science into meaningful impact.
Jennifer Herington, PhD
CO-FOUNDER MATERNAL HEALTH
Dr. Herington is a reproductive biologist
focused on uterine physiology and the
molecular drivers of preterm labor
Todd D. Giorgio, PhD
CO-FOUNDER ADVANCED DRUG DELIVERY
Dr. Giorgio is a biomedical engineer
pioneering targeted drug delivery and
translational nanotherapeutics
Camille V. Trinidad, PhD
BUSINESS DEVELOPMENT & RESEARCH SCIENTIST
Andrew Cothrell, PhD
DRUG DEVELOPMENT & CHARACTERIZATION SCIENTIST
ADVISORY BOARD
Guided by leaders in maternal-fetal medicine, neonatology, and drug development
Our advisors bring the clinical, regulatory, and translational expertise required to move uterus-targeted therapeutics from the lab to the bedside.
J. Michael Newton, MD, PhD, FACOG
Maternal-Fetal Medicine
Vanderbilt University Medical Center
Michael Kates, PhD
VP, Integrated IND/NDA Program Development
Davos Pharma
Jeff Reese, MD
Neonatologist
Vanderbilt University Medical Center